{"entity":{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","aka":["Nerviano Medical Sciences Ltd.","Nerviano Medical Sciences (Shanghai) Ltd.","Nerviano Medical Sciences S.r.l.","NMS"],"tldr":"Nerviano Medical Sciences is an Italian drug-discovery company founded in 2004 in Nerviano, near Milan, that leads two cancer trials in OnCo: the PARP1-selective inhibitor atamparib in advanced solid tumours and NMS-03305293 with temozolomide in recurrent glioblastoma.","summary":"Nerviano Medical Sciences is a company based in Nerviano, Italy, founded in 2004 (Wikidata Q30280722, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor; its Shanghai subsidiary is the registered sponsor of one trial. It leads two phase 1/2 trials recorded in OnCo: NCT07374419 (atamparib in advanced solid tumours, recorded under NSCLC) and NCT04910022 (NMS-03305293 with temozolomide in adults with recurrent glioblastoma). Both compounds are its own, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Official website","url":"http://www.nervianoms.com/en/"},{"label":"Wikidata Q30280722","url":"https://www.wikidata.org/wiki/Q30280722"},{"label":"ClinicalTrials.gov: trials led by Nerviano Medical Sciences","url":"https://clinicaltrials.gov/search?lead=Nerviano%20Medical%20Sciences"}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["nsclc","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07374419","nct04910022"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Nerviano","country":"IT","companyType":"biotech","website":"http://www.nervianoms.com/en/","founded":2004,"investors":[],"funding":[]},"route":"/companies/nerviano-medical-sciences/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"trial":[{"id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/"},{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/"}]}}